Johnson & Johnson Private Limited clinical trials

A country office of Johnson & Johnson

The registry lists 9 studies whose lead sponsor is Johnson & Johnson Private Limited. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.

Studies

Recruiting first, then most recently updated. Showing 9 of 9. All Johnson & Johnson studies →

• A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)RecruitingNCT07141004Phase 4

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaActive, not recruitingNCT07030517Phase 4

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p DeletionCompletedNCT03190330Phase 4

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With DiabetesCompletedNCT04288778Phase 4

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic ArthritisCompletedNCT03733925Phase 4

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory AgentCompletedNCT03768960Phase 4

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaCompletedNCT03476655

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate CancerWithdrawnNCT02608359

  Sponsor listed in the registry: Johnson & Johnson Private Limited

• A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical SettingCompletedNCT03604224

  Sponsor listed in the registry: Johnson & Johnson Private Limited